Gsk Plc Stock Net Income
| GLAXF Stock | USD 28.24 0.10 0.36% |
As of the 10th of February, GSK Plc retains the Market Risk Adjusted Performance of (0.81), risk adjusted performance of 0.117, and Semi Deviation of 2.59. GSK Plc technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out GSK plc information ratio, as well as the relationship between the value at risk and expected short fall to decide if GSK Plc is priced correctly, providing market reflects its last-minute price of 28.24 per share. Given that GSK plc has jensen alpha of 0.5018, we strongly advise you to confirm GSK plc's regular market performance to make sure the company can sustain itself at some point in the future.
GSK Plc's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing GSK Plc's valuation are provided below:GSK plc does not now have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. GSK |
GSK Plc 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to GSK Plc's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of GSK Plc.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in GSK Plc on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding GSK plc or generate 0.0% return on investment in GSK Plc over 90 days. GSK Plc is related to or competes with Chugai Pharmaceutical, Sanofi, Chugai Pharmaceutical, CSL, Daiichi Sankyo, MERCK Kommanditgesells, and Merck KGaA. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of ... More
GSK Plc Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure GSK Plc's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess GSK plc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.16 | |||
| Information Ratio | 0.1074 | |||
| Maximum Drawdown | 16.43 | |||
| Value At Risk | (5.63) | |||
| Potential Upside | 6.6 |
GSK Plc Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for GSK Plc's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as GSK Plc's standard deviation. In reality, there are many statistical measures that can use GSK Plc historical prices to predict the future GSK Plc's volatility.| Risk Adjusted Performance | 0.117 | |||
| Jensen Alpha | 0.5018 | |||
| Total Risk Alpha | 0.079 | |||
| Sortino Ratio | 0.0876 | |||
| Treynor Ratio | (0.82) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GSK Plc's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
GSK Plc February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.117 | |||
| Market Risk Adjusted Performance | (0.81) | |||
| Mean Deviation | 2.39 | |||
| Semi Deviation | 2.59 | |||
| Downside Deviation | 4.16 | |||
| Coefficient Of Variation | 733.53 | |||
| Standard Deviation | 3.4 | |||
| Variance | 11.53 | |||
| Information Ratio | 0.1074 | |||
| Jensen Alpha | 0.5018 | |||
| Total Risk Alpha | 0.079 | |||
| Sortino Ratio | 0.0876 | |||
| Treynor Ratio | (0.82) | |||
| Maximum Drawdown | 16.43 | |||
| Value At Risk | (5.63) | |||
| Potential Upside | 6.6 | |||
| Downside Variance | 17.34 | |||
| Semi Variance | 6.72 | |||
| Expected Short fall | (3.36) | |||
| Skewness | (0.03) | |||
| Kurtosis | 0.5019 |
GSK plc Backtested Returns
GSK Plc appears to be not too volatile, given 3 months investment horizon. GSK plc holds Efficiency (Sharpe) Ratio of 0.13, which attests that the entity had a 0.13 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for GSK plc, which you can use to evaluate the volatility of the firm. Please utilize GSK Plc's Risk Adjusted Performance of 0.117, semi deviation of 2.59, and Market Risk Adjusted Performance of (0.81) to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, GSK Plc holds a performance score of 10. The company retains a Market Volatility (i.e., Beta) of -0.55, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning GSK Plc are expected to decrease at a much lower rate. During the bear market, GSK Plc is likely to outperform the market. Please check GSK Plc's total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether GSK Plc's current trending patterns will revert.
Auto-correlation | 0.19 |
Very weak predictability
GSK plc has very weak predictability. Overlapping area represents the amount of predictability between GSK Plc time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of GSK plc price movement. The serial correlation of 0.19 indicates that over 19.0% of current GSK Plc price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.19 | |
| Spearman Rank Test | 0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 2.18 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, GSK plc reported net income of 14.96 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all United States stocks is significantly lower than that of the firm.
GSK Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GSK Plc's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of GSK Plc could also be used in its relative valuation, which is a method of valuing GSK Plc by comparing valuation metrics of similar companies.GSK Plc is currently under evaluation in net income category among its peers.
GSK Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X | |||
| Price To Sales | 1.91 X | |||
| Revenue | 29.32 B | |||
| Gross Profit | 19.92 B | |||
| EBITDA | 8.8 B | |||
| Net Income | 14.96 B | |||
| Cash And Equivalents | 6.53 B | |||
| Cash Per Share | 1.62 X | |||
| Total Debt | 19.76 B | |||
| Debt To Equity | 0.98 % | |||
| Current Ratio | 1.43 X | |||
| Book Value Per Share | 2.63 X | |||
| Cash Flow From Operations | 7.4 B | |||
| Earnings Per Share | 1.32 X | |||
| Price To Earnings To Growth | 1.11 X | |||
| Number Of Employees | 45 | |||
| Beta | 0.28 | |||
| Market Capitalization | 73.5 B | |||
| Total Asset | 60.15 B | |||
| Retained Earnings | (6.55 B) | |||
| Working Capital | (525 M) | |||
| Current Asset | 17.61 B | |||
| Current Liabilities | 18.14 B | |||
| Z Score | 1.8 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 5.36 % | |||
| Net Asset | 60.15 B | |||
| Last Dividend Paid | 0.61 |
About GSK Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GSK plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GSK Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GSK plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in GSK Pink Sheet
GSK Plc financial ratios help investors to determine whether GSK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.